Basic Information
| LncRNA/CircRNA Name | LSINCT5 |
| Synonyms | NA |
| Region | GRCh38_5:2712591-2715237 |
| Ensemble | |
| Refseq | NR_145480 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, Western blot, in vitro knockdown, RIP |
| Sample | bladder cancer tissues, cell lines (UBC-40, T24, SW780, RT4 and J82) |
| Expression Pattern | up-regulated |
| Function Description | LSINCT5 is significantly upregulated in human bladder cancer cell lines and tumor specimens. Meanwhile, high LSINCT5 expression correlates with poor prognosis, enhances tumor sphere formation and invasion in vitro. In vivo xenograft tumor growth is also elevated by LSINCT5 overexpression. Mechanistic investigations showed that LSINCT5 could physically interact with NCYM, a de novo gene product from the MYCN cis-antisense RNA and inhibit GSK3? activity leading to enhanced Wnt/?-catenin signaling activation and epithelial mesenchymal transition (EMT). |
| Pubmed ID | 29772237 |
| Year | 2018 |
| Title | LSINCT5 Activates Wnt/?-catenin Signaling by Interacting With NCYM to Promote Bladder Cancer Progression |
External Links
| Links for LSINCT5 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |